Champions Oncology (NASDAQ:CSBR) announced its earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.15), Fidelity Earnings reports. The company had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $8.48 million. Champions Oncology had a negative net margin of 6.14% and a negative return on equity of 64.00%.

Shares of NASDAQ:CSBR traded up $0.08 during midday trading on Friday, hitting $9.13. The company had a trading volume of 2,115 shares, compared to its average volume of 51,216. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.12 and a quick ratio of 0.96. The company has a market cap of $115.18 million, a price-to-earnings ratio of -50.72 and a beta of 1.27. Champions Oncology has a 12-month low of $4.02 and a 12-month high of $10.89. The company has a fifty day moving average of $9.35 and a two-hundred day moving average of $8.01.

Separately, Zacks Investment Research lowered shares of Champions Oncology from a “buy” rating to a “hold” rating in a research note on Friday, June 26th.

Champions Oncology Company Profile

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Featured Article: Convertible Shares

Earnings History for Champions Oncology (NASDAQ:CSBR)

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with's FREE daily email newsletter.